Currently, researchers have developed a variety of TLRs agonists such as poly (I: C) and lipopolysaccharide, agonists of TLR3 and TLR4, both of which can activate M1 macrophages to produce the anti-tumor effector molecule NO, thus inhibiting tumor growth (Müller et al., 2018). This evidence concerns the gene TLR3 and neoplasm.